- U.S.
- World
- Science
- Health
- Life
- Rankings
- Opinion
- Entertainment
- Fact Check
- My Turn
- Education
- EventsSportsPodcastsBetter PlanetBetter WorkplacesMightierAutosNewslettersUnconventionalVantageExpertsLeadershipDev Pragad
- Subscribe
- Login
×
Subscribe Login
- U.S.
- World
- Science
- Health
- Life
- Rankings
- Opinion
- Entertainment
- Fact Check
- My Turn
- Education
- Events
- Sports
- Podcasts
- Better Planet
- Better Workplaces
- Mightier
- Autos
- Newsletters
- Unconventional
- Vantage
- Experts
- Leadership
- Dev Pragad
Delphine Groll
Home > Rankings Portal
Share
Share on Facebook Share on Twitter Share on LinkedInShare on RedditShare on Flipboard Share via Email Comments

Delphine Groll
Nabla
Co-Founder & COO at Nabla
Company Info
Nabla
1 Dock 72 Wy
Brooklyn NY 11249
About
As co-founder and COO of Nabla, Delphine Groll is scaling one of the most widely adopted clinical AI platforms in the U.S., helping clinicians document visits, capture accurate codes, and reduce administrative burden across care settings. Under her leadership, Nabla has become a trusted partner to hundreds of healthcare organizations and tens of thousands of clinicians, including CVS Health, Children's Hospital Los Angeles, Denver Health, and University of Iowa Health Care, supporting more than 40 million patient encounters annually. She has helped scale the company through rapid growth, strategic partnerships with leading health systems and EHR providers, and $120 million in funding, including a $70 million Series C. Her leadership has earned recognition from Inc.’s Female Founders 500 (2026) and Becker’s Women in Health IT to Know (2026) and Becker’s Healthcare’s 100 Healthcare Leaders Under 40 (2025).Before co-founding Nabla, Groll served at the Office of the President of France, where she helped shape national strategy for major international sporting events, including initiatives related to the Paris Olympics. Today, she is a board member and investor at The Galion Project and actively supports the next generation of founders and leaders in healthcare and AI.
Education
- Public Administration
Ecole Normale Supérieur Ulm - University of Paris I - La Sorbonne, 2010 - Masters in Public Affairs, Political Sciences
Science Po Aix-en-Provence, 2009
Awards & Certifications
- Becker’s Hospital Review: Rising Stars: 100 Healthcare Leaders Under 40 | 2025
- Crain’s New York Business: 31 Notable Leaders in Healthcare Technology
- Inc.: Female Founders 500 | 2026
- Becker’s Hospital Review: Women in Health IT to Know | 2026
Philanthropic Endeavors
- She invests in and advises health and technology startups led by women and uses her position to open doors for others in the field. She mentors founders through Women in AI, Women Leading Health Care, and the Galion Project, and serves on the board of ConnectHer.
Delphine Groll, co-founder and COO of health tech company Nabla, has spent the past several years at the intersection of artificial intelligence and clinical care—helping bring clinical AI into everyday practice at health systems across the country. In this conversation, she discusses Nabla's ambient AI assistant, turning AI skepticism into cautious adoption driven by frontline experience and how Nabla has scaled its technology beyond pilot programs by focusing on clinician feedback, customization and workflow integration. Groll also discusses how her company is measuring real-world impacts, creating opportunities for women in the industry and the importance of keeping human touch remains at the center of patient care.
How has your thinking on the relationship between AI and clinicians evolved? What have you seen in practice that has most shaped that view?
The relationship between AI and clinicians started with a fair amount of skepticism. Only a few years ago, clinicians questioned whether AI was reliable, safe or ultimately a replacement for their role. What has shifted that perspective is not messaging, but experience. As the technology improved and the benefits became tangible, clinicians began to see meaningful impact in their day-to-day practice.
That shift from skepticism to trust has been striking. At Nabla, we hear clinicians tell us everyday how they would not want to practice without AI. Some even say it has helped them stay in medicine longer.
What is important is that this has been a partnership. The technology has improved because clinicians engaged with it, challenged it and helped shape how it works in real clinical settings.
Looking ahead, as we move toward more agentic AI, I think clinicians will increasingly see these systems as work companions.
When health systems begin adopting AI, what tends to get underestimated? Can you share a specific example where implementation was more complex—or more successful—than expected?
One thing that often gets underestimated is the role of change management. When people see the potential of AI, there is a tendency to assume adoption will be seamless and organic.
And in some cases, that is true. You do have groups of highly engaged, tech-forward clinicians who are eager to adopt AI. But that is not the full picture. There is always a broader group that needs more support, training and reassurance.
Even with an intuitive product, adoption requires intentional onboarding, workflow integration and ongoing support. Every organization and every clinician documents differently, so there is also a level of customization needed to ensure the tool fits naturally into their practice.
At the same time, we have also seen the upside surprise us. In one case, after implementing our ambient AI at Denver Health, Dr. Daniel Kortsch, the associate chief of AI and digital health, shared that clinicians sent a box of chocolates to thank the team. That is not something you typically see with hospital IT rollouts.
Many organizations struggle to move AI beyond pilot programs. How has Nabla approached scaling in a way that delivers system-wide impact? What tradeoffs were required to make that happen?
At Nabla, we approach scaling as an operational challenge. We build strong feedback loops with our partners and turn that input into concrete improvements across product, training and support. That creates a repeatable model where each deployment benefits from the last.
We also invest heavily in training and onboarding. Because workflows vary widely, we develop role-based and specialty-specific resources, along with short, workflow-integrated materials that fit naturally into clinicians' day to day. Reducing friction at the point of care is what allows adoption to expand beyond initial pilots.
There are tradeoffs. This approach requires more upfront investment and a willingness to adapt based on feedback. But that discipline is what enables durable, system-wide impact rather than limited experimentation.
When evaluating whether AI is truly delivering value, what metrics or signals matter most to you? Can you share a specific example of how you determined whether something was—or wasn't—working?
When we evaluate whether AI is delivering value, we focus on a combination of efficiency, clinician well-being, and patient experience.
We track clear quantitative signals like time saved on documentation, reduction in after-hours work and overall adoption rates. But we also look closely at qualitative indicators like how much editing clinicians are doing, whether the note reflects their voice and whether Nabla fits naturally into their workflow.
Adoption is often the clearest signal. At one point, we saw lower-than-expected adoption in a specific organization. Rather than assuming a lack of interest, we dug deeper and spent time with clinicians to understand what was happening.
What we found was not a product issue, but a fit issue. Clinicians needed more customization and more support during onboarding to feel confident using the tool in their day-to-day practice.
In response, we introduced a more robust customization interface so clinicians can tailor the product to their preferences from the moment they start using it. We also expanded onboarding with both in-person and virtual office hours.
That shift led to a meaningful increase in adoption. It reinforced a core principle for us: Value is not just about performance; it is about whether the product works for the clinician in their specific context.
As a woman building in health care and AI, what have you found actually works when it comes to supporting and amplifying other women? Are there specific actions that have a lasting impact?
It still surprises me how often you see panels, leadership forums or decision-making groups without women, especially in healthcare. That does not change on its own. You have to actively create space and ensure diverse voices are present wherever decisions are being made.
Finally, it is about using your position, your expertise, your experience, and what you've learnt, to create opportunities for others. That can mean investing in or advising women-led startups, mentoring founders or simply making introductions that would not have happened otherwise. In my case, I like to spend time working with communities like Women in AI and Women Leading Healthcare.
The common thread is that impact comes from action. Small, consistent efforts to open doors and address structural gaps are very important.
At a product level, where has Nabla's AI delivered the most meaningful impact so far? What specifically drove those results and where is it still room for progress to be made?
The most meaningful impact so far has been in reducing documentation burden and improving the day-to-day experience of clinicians. Our ambient AI assistant has delivered measurable results, with peer reviewed studies and real-world deployments showing documentation time cut by more than half, reductions in burnout and increases in patient satisfaction.
Rather than building point solutions, we focused on a workflow-native assistant that integrates directly into the [Electronic Health Records] EHR and supports clinicians in real time. That combination of accuracy, speed and seamless fit is what has driven strong adoption across diverse care settings.
For the coming months, we are focused on scaling our coding engine across major specialties and health systems, while helping our partners more clearly measure and realize the financial returns from those workflows.
We are also partnering with Advanced Machine Intelligence Labs, founded by Yann LeCun, to bring world models into healthcare. This will allow us to move beyond copilot-style systems toward AI agents that can reason, adapt and interact with complex clinical environments, with higher accuracy and reliability.
There is often tension between improving clinician experience and maintaining financial sustainability. How have you approached balancing those priorities? Can you share a specific decision that illustrates that tradeoff?
We do not see it as a tradeoff. In fact, it's quite the opposite. If you get clinician experience right, the financial value tends to follow. A lot of health systems we work with think about ROI in terms of clinician and patient satisfaction, retention, talent attraction, etc. We can't overlook the fact that replacing a physician can cost hospitals between $500,000 and $1 million per hire.
Internally, a good example is the level of investment we made in building a highly accurate ambient documentation engine. Coding works best when it is grounded in the clinical context captured during the encounter itself. When the documentation layer is accurate and deeply embedded into clinician workflows, the downstream financial and administrative value becomes much easier to realize.
That decision meant slower short-term monetization in some areas, but it created a foundation where clinicians actually use the product consistently. From there, expanding into areas like coding becomes much more effective and sustainable.
Trust and safety are critical in health care AI. How does Nabla decide where to move quickly versus where to be more cautious? Can you share an example of a boundary you chose not to cross?
In healthcare AI, deciding where to move quickly versus cautiously comes down to the level of risk and autonomy.
We move fast in areas that improve workflow efficiency and clinician experience. But we are much more deliberate when it comes to anything that involves access to patient data, clinical judgment or actions taken on behalf of a clinician.
A big part of that is recognizing that true autonomy in healthcare depends on deep integrations, clear access controls and a robust governance framework around who the system is acting for, what it is allowed to do and how those actions are audited. Those pieces are still maturing across the industry.
So, a clear boundary we've chosen not to cross is fully autonomous decision-making. Even as we move toward more agentic capabilities, we keep clinicians in the loop, especially for anything that touches clinical decisions, coding or patient outcomes.
In practice, that means we lean into hybrid workflows. The AI can draft, suggest and streamline, but the clinician reviews and validates. That approach delivers meaningful efficiency gains today while maintaining the level of safety and accountability that healthcare requires.
In this space, trust is not just about how fast you move, but about being disciplined in where you don't.
As Nabla has scaled, can you share a moment where you had to introduce guardrails or processes to ensure transparency or accountability? What prompted that decision?
A good example is when we decided to formalize and publish our model card through CHAI. The Coalition for Health AI brings together leaders across the ecosystem to advance AI in healthcare with a strong focus on safety, transparency and trust, which closely aligns with our own approach.
As Nabla scaled and engaged with more health systems, we saw a clear shift in expectations. Buyers were no longer satisfied with traditional vendor documentation. They wanted structured, detailed answers on how models are trained, how data is used, how performance is monitored and how risks are managed.
Publishing a model card and participating in the CHAI registry allowed us to meet that moment. It gave us a standardized way to share this information transparently and made it easier for health systems to evaluate us alongside other vendors.
Can you share a specific moment—at Nabla or earlier in your career—when you saw firsthand how AI could meaningfully change a clinician's day?
Early on, before Nabla became the AI assistant it is today, we explored a range of AI capabilities for clinicians. We initially assumed that clinical decision support would be the most impactful. In reality, it was the administrative support that resonated most.
That was an important learning. Clinicians do not want AI to replace the parts of their work they value most, which is caring for patients. They want it to remove the repetitive, administrative burden around that care.
One moment that really brought this to life came from a clinician using Nabla during a phone visit with a patient who had a speech impairment. There were parts of the conversation that were difficult to understand in real time. When the clinician later reviewed the transcript, he noticed the patient had mentioned that the patient's brother helps manage appointments, something he had not caught during the call.
The clinician followed up, confirmed it and was able to involve the brother in the care plan. Without that, the patient might have faced delays or gaps in follow-up.
It is a small moment, but it captures the impact well. AI is not replacing the clinician. It is helping ensure that important details are not lost, so care can be more complete and more reliable.
What's a piece of feedback you received that meaningfully changed how you lead? What was the context, and how did it change your approach?
One of the most valuable lessons I have learned came from a sentence someone shared with me over dinner years ago: People may forget what you said, but they will remember how you made them feel. There are moments when I need to lead difficult meetings, meet with important clients, and recruit exceptional people. And when the personal stakes feel high, I try to remember that sentence. It helps me step back, focus less on myself and approach the situation with more perspective.
Delphine Groll is a member of the Newsweek CEO Circle, an invite-only executive community of subscribers.
Visit our rankings portal
Back To Top
U.S.WorldScienceHealthRankingsOpinionEntertainmentFact CheckMy TurnEducationEventsSportsPodcastsBetter PlanetBetter WorkplacesMightierAutosNewslettersUnconventionalVantageExpertsLeadershipDev Pragad
Trending
Israel at War Vladimir Putin Russia-Ukraine War Donald Trump
Subscriptions
Membership Monthly $4.99 Membership Yearly $49.00 Membership+Print Monthly $9.99 Membership+Print Yearly $99
Newsletters in your inbox See all
The Bulletin (Daily)See Sample
The Gist of It (Daily)
Geoscape (Twice a Week)
The 1600 (Daily)
Inside Trump Policy (Weekly)
Newsweek AI (Weekly)
Sports Daily (Daily)
The Josh Hammer Report (Weekly)See Sample
For The Culture (Three Times a Week)See Sample
Discoveries (3 Times a Week)
Like & Subscribe (Daily)
Breaking News (As it Breaks)
The Debate (Twice a Week)
Pawsitively (Daily)
Better Planet (Weekly)
The Good Life (Weekly)
Newsweek Pulse (2x3 Times a Month)
Sign up now
You can unsubscribe at any time. By signing up you are agreeing to our Terms of Service and Privacy Policy
In The Magazine
September 19
2025 Issue
Company
About UsMastheadDiversityAnnouncementsArchivePolicies and StandardsMission StatementLeadershipNewslettersPress Center
Editions:
Contact
AdvertiseCareersContact UsCorrections
Terms of Use
Cookie PolicyCopyrightPrivacy PolicyTerms & ConditionsTerms of Sale Privacy Settings
© 2026 NEWSWEEK DIGITAL LLC
